SV Life Sciences has hired experienced venture capital investor Michael Balmuth as a partner in its healthcare services team not long after adding three new venture partners to its biotechnology investment division.

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

Investors including the Halifax Group, SV Life Sciences and Comvest Partners have exited their stake in biopharmaceutical and medical device development services company Aptiv Solutions to ICON for $143.5m.